分析师在报告中写道："在2027年及以后增长路径不清晰的情况下，30倍的估值倍数难以合理化。"他们 指出，即便采用更合理的估值倍数，其对应的业务规模"也似乎极难实现"——当前最大的争议点在于公 司签署订单的速度："正如管理层此前所言，达成大型订单需要时间。我们并非低估Bloom Energy最终 实现1吉瓦以上业务规模的能力，但短期内看不到这一目标落地的可能。" Bloom Energy(BE.US)股价在周三暴跌，一度下挫16.5%，周三收跌10.6%。此前，杰富瑞将该股评级 从"持有"下调至"跑输大盘"，并给出31美元的目标价，理由是2026年后公司增长前景不明朗，且已出 现"早期过度乐观迹象"。 以杜尚特.阿伊拉尼(Dushyant Ailani)为首的杰富瑞分析师团队表示，Bloom Energy在前景可期的细分领 域确实处于领先地位，但其众多乐观增长假设正面临现实制约。当前该股估值对应2027财年预期 EBITDA(息税折旧摊销前利润)约31倍，已隐含对高增长的预期，而下行风险已超过进一步上涨的可能 性。 杰富瑞认为，除了包含实质性订单数据外，该股下一个潜在催化剂将出现在2月26日——届时Bloom ...

Core Viewpoint - UBS reiterated a "Buy" rating for Elevance Health (ELV.US) with a target price of $435, indicating a potential upside of nearly 53% from the recent closing price of $283.48 [1] Financial Performance - Elevance Health reported Q2 revenue of $49.8 billion, exceeding market expectations [1] - Adjusted earnings per share (EPS) for Q2 were $8.84, in line with market expectations [1] - The company lowered its full-year EPS forecast by $4.50, equating to a pre-tax profit reduction of $1.3 billion [1] Future Projections - Elevance Health raised its 2025 medical loss ratio forecast by 90 basis points [1] - The increase in medical loss ratio expectations is attributed to unfavorable cost trends in the Affordable Care Act (ACA) transactions and Medicaid business [1] Investment Rationale - UBS maintains a "Buy" rating due to the potential profitability stability and growth opportunities in the commercial insurance and Carelon business segments, despite the raised medical loss ratio expectations [1]

Core Viewpoint - The Governor of the Bank of Japan, Kazuo Ueda, stated that the growth outlook remains fundamentally unchanged [1] Group 1 - The Bank of Japan's growth prospects have not seen significant alterations despite ongoing economic conditions [1]

通胀将持续稳定在2%左右。 欧洲央行行长拉加德：预计近期增长前景趋弱。 增长前景的风险仍偏向下行。 欧洲央行处于有利位置以应对不确定时期。 ...